Effect of aerobic exercise and 25 hydroxy vitamin D supplementation on type 2 diabetes

Effect of aerobic exercise and 25 hydroxy vitamin D supplementation on ratio of GLP1 and DPP4 and Insulin resistance In men with type 2 diabetes

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017010315812N3

Enrollment

Registered

2017-03-08

Start date

2017-01-14

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Control group : This group have not any physical activity or 25-hydroxyvitamin D3 supplements. Intervention 2: Aerobic exercise group : Exercise program will be include 8 weeks (3sess

Treatment - Drugs

Behavior

Control group : This group have not any physical activity or 25-hydroxyvitamin D3 supplements

Aerobic exercise group : Exercise program will be include 8 weeks (3sessions in week, each session 60-75 minutes, the intensity of exercise was 60 to 80 percent of maximum heart rate).

Aerobic exercise with 25-Hydroxy Vitamin D3 supplementation group: This group, In addition of Exercise Performance for 8 weeks (3sessions in week, each session 60-75 minutes, the intensity of exerci

Supplemented groups: this group will be receive 25-Hydroxy Vitamin D3 with dose 50000 units, One tablet per week for 8 weeks

Eligibility

Sex/Gender

Male

Age

40 Years to 60 Years

Inclusion criteria

Inclusion criteria: Terms of enter the major conditions: Male? Type 2 diabetes Infection according to diagnosis and medical records for more than a year? Aged 40 to 60 years? Not doing regular physical activity? Do not use Insulin? Lack of complications of diabetes Including Diabetic foot ulcers? Blood glucose less than250(mg/dl)? HBA1C Less than 8. Exclusion major conditions: Absence in the exercise? Lack of supplementation in doses specified? Consumption Insulin.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Glucagonlike Peptide -1(GLP1). Timepoint: The first day and 8 weeks after. Method of measurement: Elisa.;Dipeptidyl Peptidase-4. Timepoint: The first day and 8 weeks after. Method of measurement: Elisa.;Insulin Resistant. Timepoint: The first day and 8 weeks after. Method of measurement: Fasting Blood Sugar*Serum Insulin /405.	—

Secondary

Measure	Time frame
Serum Insulin. Timepoint: The first day and 8 weeks after. Method of measurement: Blood Sample.;Fasting Blood Sugar. Timepoint: The first day and 8 weeks after. Method of measurement: Elisa.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNaesr Rahimi

Bu Ali Sina University, Hamedan

n.rahimi2009@yahoo.com+98 31 3612 2649

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026